MPD 003
Alternative Names: MPD-003Latest Information Update: 28 Apr 2024
At a glance
- Originator MedPacto
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Solid-tumours in South Georgia
- 22 Mar 2020 MPD 003 is available for licensing as of 22 Mar 2020. http://www.medpacto.com/page/s3/s1.php
- 19 Mar 2020 Preclinical trials in Solid tumours in South Georgia (unspecified route) before March 2020 (MedPacto pipeline March 2020)